- Home
- UAN vs REPL Comparison
UAN vs REPL Comparison
Compare UAN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- REPL
- Stock Information
- Founded
- UAN 2007
- REPL 2015
- Country
- UAN United States
- REPL United States
- Employees
- UAN N/A
- REPL N/A
- Industry
- UAN Agricultural Chemicals
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- REPL Health Care
- Exchange
- UAN Nasdaq
- REPL Nasdaq
- Market Cap
- UAN 793.5M
- REPL 780.3M
- IPO Year
- UAN 2011
- REPL 2018
- Fundamental
- Price
- UAN $81.47
- REPL $14.01
- Analyst Decision
- UAN
- REPL Strong Buy
- Analyst Count
- UAN 0
- REPL 6
- Target Price
- UAN N/A
- REPL $19.67
- AVG Volume (30 Days)
- UAN 36.3K
- REPL 816.7K
- Earning Date
- UAN 02-18-2025
- REPL 02-14-2025
- Dividend Yield
- UAN 8.19%
- REPL N/A
- EPS Growth
- UAN N/A
- REPL N/A
- EPS
- UAN 4.97
- REPL N/A
- Revenue
- UAN $527,388,000.00
- REPL N/A
- Revenue This Year
- UAN N/A
- REPL N/A
- Revenue Next Year
- UAN N/A
- REPL $300.41
- P/E Ratio
- UAN $16.26
- REPL N/A
- Revenue Growth
- UAN N/A
- REPL N/A
- 52 Week Low
- UAN $61.62
- REPL $4.92
- 52 Week High
- UAN $88.94
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- UAN 57.61
- REPL 62.26
- Support Level
- UAN $80.28
- REPL $13.33
- Resistance Level
- UAN $83.76
- REPL $14.52
- Average True Range (ATR)
- UAN 2.29
- REPL 0.93
- MACD
- UAN -0.24
- REPL 0.22
- Stochastic Oscillator
- UAN 29.49
- REPL 85.16
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.